Business, energy, technology, markets and global industry news from Business News Today

solid tumors

PharmaDeviceNews solid tumors
Representative image of a bispecific antibody-drug conjugate in a cancer research setting, illustrating the science behind CStone Pharmaceuticals’ AACR 2026 update on CS5007, CS5006, and CS5008 oncology pipeline candidates.
Pharma & Biotech

Why CStone Pharmaceuticals’ CS5007 may be the most important asset in its AACR 2026 antibody-drug conjugate update

CStone Pharmaceuticals unveiled three ADC programs at AACR 2026. Read what CS5007, CS5006, and CS5008 could mean for oncology development.

Read More
Pharma & Biotech

Salubris Biotherapeutics expands JK06 data at AACR 2026 with encouraging responses in difficult solid tumors

Salubris Biotherapeutics’ JK06 showed early AACR 2026 activity in NSCLC and breast cancer. Read what it could mean for the 5T4 ADC race.

Read More
Pharma & Biotech

Can OncoNano Medicine’s ON-BOARD platform solve antigen limits in solid tumor drug delivery?

OncoNano Medicine’s AACR 2026 data spotlight ON-BOARD and ONM-421. Read why pH-targeted tumor delivery could reshape oncology development.

Read More
Representative image of a scientist in a cancer research laboratory, illustrating Onchilles Pharma’s AACR 2026 preclinical update on the NEU-002 systemic solid tumor therapy program.
Pharma & Biotech

How NEU-002 could reshape Onchilles Pharma’s systemic solid tumor strategy after AACR 2026

Onchilles Pharma’s NEU-002 showed systemic anti-tumor activity at AACR 2026. Read what the preclinical data could mean for solid tumor development.

Read More
Representative image of bispecific antibody drug conjugate research as NEOK Bio highlights NEOK001 and NEOK002 at AACR 2026, drawing attention to the next wave of solid tumor ADC development.
Pharma & Biotech

Can bispecific ADCs give NEOK Bio a more credible route into solid tumor drug development?

NEOK Bio unveiled AACR 2026 data for NEOK001 and NEOK002. Read how its bispecific ADC strategy could reshape solid tumor competition.

Read More
Representative image of preclinical oncology research linked to Soley Therapeutics’ STX-6398 program, highlighting the growing interest in CKAP2-targeted cancer drug discovery after AACR 2026.
Pharma & Biotech

Soley Therapeutics shows early tumor selectivity for STX-6398, but can CKAP2 modulation scale?

Soley Therapeutics unveiled AACR 2026 data for STX-6398. Read why CKAP2 modulation could open a new path in oncology.

Read More
Pharma & Biotech

Why ABION’s ABN202 may be aiming beyond TROP2 antibody-drug conjugate resistance

ABION’s ABN202 showed preclinical promise against TROP2 ADC resistance at AACR 2026. Read what this could mean for solid tumor oncology.

Read More
Pharma & Biotech

Can Calidi Biotherapeutics, Inc.’s RedTail platform solve the solid tumor T-cell engager problem?

Calidi Biotherapeutics, Inc. unveils new RedTail and TROP-2 data at AACR 2026. Read what this means for solid tumor immunotherapy and CLD-401 next.

Read More
Pharma & Biotech

What the NEOK002 IND milestone changes for Biocytogen, NEOK Bio, and ADC competition

NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.

Read More
Pharma & Biotech

Why Precision Biologics is betting on tumor-specific neoepitopes to reshape monoclonal antibody cancer therapy

Precision Biologics highlights tumor-specific monoclonal antibodies at Festival of Biologics USA. Discover how neoepitope targeting could reshape cancer therapy.

Read More